Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- 05 Jan 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 19 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 09 May 2016 Status changed from active, no longer recruiting to recruiting.